V Wee Yong

Summary

Affiliation: University of Calgary
Country: Canada

Publications

  1. ncbi Inflammation in neurological disorders: a help or a hindrance?
    V Wee Yong
    University of Calgary, Calgary, Alberta, Canada
    Neuroscientist 16:408-20. 2010
  2. ncbi A novel anti-EMMPRIN function-blocking antibody reduces T cell proliferation and neurotoxicity: relevance to multiple sclerosis
    Smriti M Agrawal
    Departments of Clinical Neurosciences and Oncology, Hotchkiss Brain Institute, University of Calgary, 3330 Hospital Drive NW, Calgary, AB T2N 4N1, Canada
    J Neuroinflammation 9:64. 2012
  3. ncbi Reduced inflammation accompanies diminished myelin damage and repair in the NG2 null mouse spinal cord
    Karolina Kucharova
    Sanford Burnham Medical Research Institute, La Jolla, CA 92037, USA
    J Neuroinflammation 8:158. 2011
  4. ncbi Experimental models of neuroprotection relevant to multiple sclerosis
    V W Yong
    Hotchkiss Brain Institute and the Department of Clinical Neurosciences, University of Calgary, Alberta, Canada
    Neurology 68:S32-7; discussion S43-54. 2007
  5. ncbi Prospects for neuroprotection in multiple sclerosis
    V Wee Yong
    Departments of Oncology and Clinical Neurosciences, The University of Calgary, 3330 Hospital Drive N W, Calgary, Alberta T2N 4N1, Canada
    Front Biosci 9:864-72. 2004
  6. ncbi Metalloproteinases: mediators of pathology and regeneration in the CNS
    V Wee Yong
    Hotchkiss Brain Institute, Department of Clinical Neurosciences, University of Calgary, 3330 Hospital Drive, Calgary, Alberta T2N 4N1, Canada
    Nat Rev Neurosci 6:931-44. 2005
  7. ncbi Taking advantage of the systemic immune system to cure brain diseases
    V Wee Yong
    Hotchkiss Brain Institute and Department of Clinical Neurosciences, University of Calgary, 3330 Hospital Drive N W, Calgary, Alberta T2N 4N1, Canada
    Neuron 64:55-60. 2009
  8. ncbi Prospects of repair in multiple sclerosis
    V Wee Yong
    Hotchkiss Brain Institute and Department of Clinical Neuroscience, University of Calgary, Calgary, Canada
    J Neurol Sci 277:S16-8. 2009
  9. ncbi The promise of minocycline in neurology
    V Wee Yong
    Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada
    Lancet Neurol 3:744-51. 2004
  10. ncbi Neuroprotection by minocycline facilitates significant recovery from spinal cord injury in mice
    Jennifer E A Wells
    University of Calgary, 3330 Hospital Drive, Calgary, Alberta, Canada T2N 4N1
    Brain 126:1628-37. 2003

Collaborators

Detail Information

Publications80

  1. ncbi Inflammation in neurological disorders: a help or a hindrance?
    V Wee Yong
    University of Calgary, Calgary, Alberta, Canada
    Neuroscientist 16:408-20. 2010
    ..We consider how the inflammatory response may be beneficial or injurious, and we describe strategies to harness the beneficial aspects of neuroinflammation...
  2. ncbi A novel anti-EMMPRIN function-blocking antibody reduces T cell proliferation and neurotoxicity: relevance to multiple sclerosis
    Smriti M Agrawal
    Departments of Clinical Neurosciences and Oncology, Hotchkiss Brain Institute, University of Calgary, 3330 Hospital Drive NW, Calgary, AB T2N 4N1, Canada
    J Neuroinflammation 9:64. 2012
    ..We reported previously that blocking EMMPRIN activity reduced neuroinflammation and severity of disease in an animal model of multiple sclerosis (MS), experimental autoimmune encephalomyelitis (EAE)...
  3. ncbi Reduced inflammation accompanies diminished myelin damage and repair in the NG2 null mouse spinal cord
    Karolina Kucharova
    Sanford Burnham Medical Research Institute, La Jolla, CA 92037, USA
    J Neuroinflammation 8:158. 2011
    ..The NG2 proteoglycan is expressed by OPCs, pericytes, and macrophages/microglia. In this report we investigate the effects of NG2 on these cell types during spinal cord demyelination/remyelination...
  4. ncbi Experimental models of neuroprotection relevant to multiple sclerosis
    V W Yong
    Hotchkiss Brain Institute and the Department of Clinical Neurosciences, University of Calgary, Alberta, Canada
    Neurology 68:S32-7; discussion S43-54. 2007
    ..Further studies are needed to establish whether experimental neuroprotection strategies involving these mechanisms may be translated into preventing neurodegeneration in multiple sclerosis...
  5. ncbi Prospects for neuroprotection in multiple sclerosis
    V Wee Yong
    Departments of Oncology and Clinical Neurosciences, The University of Calgary, 3330 Hospital Drive N W, Calgary, Alberta T2N 4N1, Canada
    Front Biosci 9:864-72. 2004
    ..Finally, the prospect of an experimental treatment, minocycline, in producing neuroprotection in MS is suggested...
  6. ncbi Metalloproteinases: mediators of pathology and regeneration in the CNS
    V Wee Yong
    Hotchkiss Brain Institute, Department of Clinical Neurosciences, University of Calgary, 3330 Hospital Drive, Calgary, Alberta T2N 4N1, Canada
    Nat Rev Neurosci 6:931-44. 2005
    ..It is clear that metalloproteinases are important determinants in enabling recovery from injury to the nervous system...
  7. ncbi Taking advantage of the systemic immune system to cure brain diseases
    V Wee Yong
    Hotchkiss Brain Institute and Department of Clinical Neurosciences, University of Calgary, 3330 Hospital Drive N W, Calgary, Alberta T2N 4N1, Canada
    Neuron 64:55-60. 2009
    ....
  8. ncbi Prospects of repair in multiple sclerosis
    V Wee Yong
    Hotchkiss Brain Institute and Department of Clinical Neuroscience, University of Calgary, Calgary, Canada
    J Neurol Sci 277:S16-8. 2009
    ..This repair capacity of glatiramer acetate may contribute to the long-term well-being of patients with multiple sclerosis treated with glatiramer acetate...
  9. ncbi The promise of minocycline in neurology
    V Wee Yong
    Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada
    Lancet Neurol 3:744-51. 2004
    ..The encouraging results of minocycline in experimental neurology bode well for its therapeutic use in human neurological diseases...
  10. ncbi Neuroprotection by minocycline facilitates significant recovery from spinal cord injury in mice
    Jennifer E A Wells
    University of Calgary, 3330 Hospital Drive, Calgary, Alberta, Canada T2N 4N1
    Brain 126:1628-37. 2003
    ..Finally, a comparison of minocycline against the currently approved treatment for acute SCI in humans, methylprednisolone, demonstrated superior behavioural recovery in the minocycline-treated animals...
  11. ncbi Elevation of matrix metalloproteinases (MMPs) in multiple sclerosis and impact of immunomodulators
    V Wee Yong
    Hotchkiss Brain Institute and Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada
    J Neurol Sci 259:79-84. 2007
    ..The potential of minocycline as a therapy in MS, based on its activity as an MMP inhibitor, is discussed. Besides affecting MMPs, minocycline may have other actions that help account for its possible utility in MS...
  12. ncbi The interplay between the immune and central nervous systems in neuronal injury
    V Wee Yong
    Department of Clinical Neurosciences, University of Calgary, 3330 Hospital Drive, Calgary, Alberta, Canada T2N 4N1
    Neurology 74:S9-S16. 2010
    ..The interplay between components of the immune system and CNS contributes both to healthy brain function and to the pathogenesis of neurodegenerative diseases such as multiple sclerosis...
  13. ncbi Chondroitin sulfate proteoglycans in demyelinated lesions impair remyelination
    Lorraine W Lau
    Hotchkiss Brain Institute and the Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta
    Ann Neurol 72:419-32. 2012
    ..Chondroitin sulfate proteoglycans (CSPGs) have been reported to accumulate in MS lesions, and we thus examined the functional roles of CSPGs on oligodendrocyte precursor cells (OPCs), oligodendrocytes, and remyelination...
  14. ncbi Promoting oligodendrogenesis and myelin repair using the multiple sclerosis medication glatiramer acetate
    Viktor Skihar
    Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta T2N 4N1, Canada
    Proc Natl Acad Sci U S A 106:17992-7. 2009
    ..These results indicate that GA promotes oligodendrogenesis and remyelination through mechanisms that involve the elevation of growth factors conducive for repair...
  15. ncbi An elevated matrix metalloproteinase (MMP) in an animal model of multiple sclerosis is protective by affecting Th1/Th2 polarization
    Andrew Weaver
    University of Calgary, Calgary, Alberta, Canada
    FASEB J 19:1668-70. 2005
    ..These results emphasize that specific MMPs can have beneficial roles in inflammation, and they implicate MMPs in T effector polarization for the first time...
  16. ncbi A1 adenosine receptor upregulation and activation attenuates neuroinflammation and demyelination in a model of multiple sclerosis
    Shigeki Tsutsui
    Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta T2N 4N1, Canada
    J Neurosci 24:1521-9. 2004
    ..Thus, modulation of neuroinflammation by the A1AR represents a novel mechanism that provides new therapeutic opportunities for MS and other demyelinating diseases...
  17. ncbi Neuroinflammation and demyelination in multiple sclerosis after allogeneic hematopoietic stem cell transplantation
    Jian Qiang Lu
    Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada
    Arch Neurol 67:716-22. 2010
    ..To evaluate the effects of allogeneic hematopoietic stem cell transplantation (allo-HSCT) on the brains of persons with and without multiple sclerosis (MS) by means of postmortem histopathological examination...
  18. ncbi IVIg attenuates T cell-mediated killing of human neurons
    Angela D Janke
    Department of Oncology, Hotchkiss Brain Institute, University of Calgary, 3330 Hospital Drive, Calgary, Alberta, Canada T2N 4N1
    J Neuroimmunol 177:181-8. 2006
    ..Our results are relevant to understanding how therapies affect the MS disease process...
  19. ncbi Depletion of Ly6G/Gr-1 leukocytes after spinal cord injury in mice alters wound healing and worsens neurological outcome
    David P Stirling
    Hotchkiss Brain Institute and Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada
    J Neurosci 29:753-64. 2009
    ....
  20. ncbi Effective combination of minocycline and interferon-beta in a model of multiple sclerosis
    Fabrizio Giuliani
    Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada
    J Neuroimmunol 165:83-91. 2005
    ..Collectively, these results suggest the utility of the combination of minocycline and interferon-beta in MS...
  21. ncbi Contributions of multiple proteases to neurotoxicity in a mouse model of intracerebral haemorrhage
    Mengzhou Xue
    Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada
    Brain 132:26-36. 2009
    ..These results provide insights into molecules that inflict neurotoxicity in ICH and demonstrate that multiple proteases would need to be targeted simultaneously to successfully reduce ICH neurotoxicity...
  22. ncbi The chemokine GRO-alpha (CXCL1) confers increased tumorigenicity to glioma cells
    Yan Zhou
    Department of Oncology, University of Calgary, Calgary, Alberta T2N 4N1, Canada
    Carcinogenesis 26:2058-68. 2005
    ..These results implicate GRO-alpha in gliomas and suggest that the dysregulation of a glia proliferative factor contributes to tumorigenesis. Targeting GRO-alpha may be a useful therapeutic tool to control brain tumor biology...
  23. ncbi Additive effect of the combination of glatiramer acetate and minocycline in a model of MS
    Fabrizio Giuliani
    Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada
    J Neuroimmunol 158:213-21. 2005
    ..This combination resulted in a significant reduction of disease severity and disease burden with attenuation of the inflammation, axonal loss and demyelination...
  24. ncbi A dialog between glioma and microglia that promotes tumor invasiveness through the CCL2/CCR2/interleukin-6 axis
    Jing Zhang
    Department of Clinical Neurosciences, Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta T2N 4N1, Canada
    Carcinogenesis 33:312-9. 2012
    ..Specifically, glioma-derived CCL2 acts upon CCR2-bearing microglia, which then produces IL-6 to stimulate gliomas. The CCL2/CCR2/IL-6 loop is a potential therapeutic target for the currently incurable malignant gliomas...
  25. ncbi The chemokine stromal cell derived factor-1 (CXCL12) promotes glioma invasiveness through MT2-matrix metalloproteinase
    Jing Zhang
    Department of Oncology, University of Calgary, Calgary, Alberta, Canada
    Carcinogenesis 26:2069-77. 2005
    ..These results highlight MT2-MMP as an effector of CXCR4 signaling in glioma cells, and they reveal the novel role of MT2-MMP in modulating tumor activity...
  26. ncbi Inflammatory cytokine modulation of matrix metalloproteinase expression and invasiveness of glioma cells in a 3-dimensional collagen matrix
    Susobhan Sarkar
    Department of Oncology, University of Calgary, Calgary, AB, Canada
    J Neurooncol 91:157-64. 2009
    ..Thus, in 3D matrix of CL, MMP-2 expression is modulated by inflammatory cytokines with the concomitant increase in glioma invasiveness...
  27. ncbi Reduction of protein kinase C delta attenuates tenascin-C stimulated glioma invasion in three-dimensional matrix
    Susobhan Sarkar
    Hotchkiss Brain Institute, Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada
    Carcinogenesis 31:311-7. 2010
    ..Our results implicate PKCdelta as a therapeutic target to reduce MMP-12 expression and glioma invasiveness when tumor cells are stimulated by the TN-enriched glioma microenvironment...
  28. ncbi Relative importance of proteinase-activated receptor-1 versus matrix metalloproteinases in intracerebral hemorrhage-mediated neurotoxicity in mice
    Mengzhou Xue
    Hotchkiss Brain Institute and Department of Clinical Neurosciences, University of Calgary, 3330 Hospital Drive, Calgary, Alberta T2N 4N1, Canada
    Stroke 40:2199-204. 2009
    ..In this study, we have investigated the relative roles of proteinase activated receptor-1, a thrombin receptor, and MMPs in brain injury induced by thrombin or blood...
  29. ncbi Association of alpha-synuclein immunoreactivity with inflammatory activity in multiple sclerosis lesions
    Jian Qiang Lu
    Department of Pathology and Laboratory Medicine, University of Calgary, Alberta, Canada
    J Neuropathol Exp Neurol 68:179-89. 2009
    ..The results suggest that alpha-synuclein expression regulated by inflammatory signals may contribute to neurodegenerative processes in MS lesions...
  30. ncbi Cleavage of osteopontin by matrix metalloproteinase-12 modulates experimental autoimmune encephalomyelitis disease in C57BL/6 mice
    Angelika Goncalves Dasilva
    Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada
    Am J Pathol 177:1448-58. 2010
    ..These results suggest that EAE disease activity may be modulated by the cleavage of OPN by MMP-12...
  31. ncbi Matrix metalloproteinase-12 deficiency worsens relapsing-remitting experimental autoimmune encephalomyelitis in association with cytokine and chemokine dysregulation
    Angelika Goncalves Dasilva
    Hotchkiss Brain Institute and Department of ClinicalNeurosciences, University of Calgary, 3330 Hospital Dr, Calgary, Alberta T2N 4N1, Canada
    Am J Pathol 174:898-909. 2009
    ..These results highlight MMP-12 as a beneficial enzyme in EAE and suggest that therapeutic interventions in multiple sclerosis should avoid targeting MMP-12...
  32. ncbi Kinetics of proinflammatory monocytes in a model of multiple sclerosis and its perturbation by laquinimod
    Manoj K Mishra
    Hotchkiss Brain Institute and the University of Calgary, Calgary, Alberta, Canada
    Am J Pathol 181:642-51. 2012
    ..These results shed light on the important role of the trafficking of proinflammatory monocytes into the CNS to promote disease activity, and they identify a mechanism of action of laquinimod in MS...
  33. ncbi Tenascin-C stimulates glioma cell invasion through matrix metalloproteinase-12
    Susobhan Sarkar
    Department of Oncology, University of Calgary, Calgary, Alberta, Canada
    Cancer Res 66:11771-80. 2006
    ..These results identify a new factor, MMP-12, in regulating glioma invasiveness through interaction with tenascin-C...
  34. ncbi An adverse role for matrix metalloproteinase 12 after spinal cord injury in mice
    Jennifer E A Wells
    Department of Clinical Neurosciences, Faculty of Medicine, University of Calgary, Calgary, Alberta T2N 4N1, Canada
    J Neurosci 23:10107-15. 2003
    ..The data indicate that MMP-12 expression after spinal cord trauma is deleterious and contributes to the development of secondary injury in SCI...
  35. ncbi Improving outcomes of neuroprotection by minocycline: guides from cell culture and intracerebral hemorrhage in mice
    Mengzhou Xue
    Hotchkiss Brain Institute, Clara Christie Centre for Mouse Genomics and Modelling of Human Disease, Department of Clinical Neurosciences, University of Calgary, 3330 Hospital Drive, Calgary, Alberta T2N 4N1, Canada
    Am J Pathol 176:1193-202. 2010
    ..We conclude that the prospect of neuroprotection with minocycline is improved by high concentrations of minocycline delivered locally into the central nervous system with supplementation from systemic administration...
  36. ncbi Minocycline attenuates T cell and microglia activity to impair cytokine production in T cell-microglia interaction
    Fabrizio Giuliani
    Department of Clinical Neurosciences, University of Calgary, Alberta, Canada
    J Leukoc Biol 78:135-43. 2005
    ..The capacity of minocycline to down-regulate CD40L on T cells may provide a new means to target the CD40-CD40L pathway, which regulates several inflammatory processes...
  37. ncbi MMPs in the central nervous system: where the good guys go bad
    Smriti M Agrawal
    Hotchkiss Brain Institute and the Department of Clinical Neuroscience, University of Calgary, Calgary, Alberta, Canada
    Semin Cell Dev Biol 19:42-51. 2008
    ..We stress the necessity of drawing a fine balance in the treatment of neurological diseases, and we suggest that MMP inhibitors do have therapeutic potential early after CNS injury...
  38. ncbi Dynamics of the inflammatory response after murine spinal cord injury revealed by flow cytometry
    David P Stirling
    Hotchkiss Brain Institute and Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada
    J Neurosci Res 86:1944-58. 2008
    ..In contrast to mobilization of neutrophils, SCI induces lymphopenia that may contribute negatively to the overall outcome after spinal cord trauma...
  39. ncbi Characterization of the early neuroinflammation after spinal cord injury in mice
    Tiffany Rice
    Hotchkiss Brain Institute and Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada
    J Neuropathol Exp Neurol 66:184-95. 2007
    ..These results of an instantaneous inflammatory response validate approaches to modulate microglia/macrophage activity to improve recovery from SCI...
  40. ncbi Matrix metalloproteinase (MMP)-12 expression has a negative impact on sensorimotor function following intracerebral haemorrhage in mice
    Jennifer E A Wells
    Department of Clinical Neurosciences, Faculty of Medicine, University of Calgary, 3330 Hospital Drive, Calgary, Alberta, T2N 4N1, Canada
    Eur J Neurosci 21:187-96. 2005
    ..The data indicate that MMP-12 expression following haemorrhagic stroke is deleterious and contributes to the development of secondary injury in this disease...
  41. ncbi Multiexponential T2 and magnetization transfer MRI of demyelination and remyelination in murine spinal cord
    Cheryl R McCreary
    Experimental Imaging Centre, University of Calgary, Calgary, AB, Canada
    Neuroimage 45:1173-82. 2009
    ..Myelin water fraction increased with remyelination, however MTR remained lower after 28 days. The difference between qT(2) and MTR may identify early remyelination...
  42. ncbi Results of a phase II placebo-controlled randomized trial of minocycline in acute spinal cord injury
    Steven Casha
    Department of Clinical Neurosciences and the Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada
    Brain 135:1224-36. 2012
    ..Although this study does not establish the efficacy of minocycline in spinal cord injury the findings are encouraging and warrant further investigation in a multi-centre phase III trial. ClinicalTrials.gov number NCT00559494...
  43. ncbi Expression and regulation of matrix metalloproteinase-12 in experimental autoimmune encephalomyelitis and by bone marrow derived macrophages in vitro
    Angelika Goncalves DaSilva
    Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada
    J Neuroimmunol 199:24-34. 2008
    ..We postulate that cytokine - MMP-12 interactions are important in the disease process of EAE...
  44. ncbi Matrix metalloproteinases in intracerebral hemorrhage
    Mengzhou Xue
    Hotchkiss Brain Institute and Department of Clinical Neurosciences, University of Calgary, Calgary, Alta, Canada
    Neurol Res 30:775-82. 2008
    ..The objective of this study is to review the role of matrix metalloproteinases in intracerebral hemorrhage, which is associated with hypertension, head trauma and premature birth...
  45. ncbi The expression of matrix metalloproteinase-12 by oligodendrocytes regulates their maturation and morphological differentiation
    Peter H Larsen
    Department of Oncology, University of Calgary, Calgary, Alberta T2N 4N1, Canada
    J Neurosci 24:7597-603. 2004
    ..We conclude that OL lineage cells express MMP-12 during their maturation and that MMP-12 activity has functional involvement both in maturation of OPCs and in the ability of OPCs and OLs to extend processes...
  46. ncbi Impact of IVIg on the interaction between activated T cells and microglia
    Angela D Janke
    Hotchkiss Brain Institute and the Departments of Clinical Neurosciences and Oncology, University of Calgary, Alta, Canada
    Neurol Res 28:270-4. 2006
    ..As a result of IVIg treatment of T cells, there were reduced levels of tumor necrosis factor-alpha a and interleukin-10 in T cell-microglia co-culture. Our results add to the understanding of how IVIg may affect inflammation of the CNS...
  47. ncbi EMMPRIN: a novel regulator of leukocyte transmigration into the CNS in multiple sclerosis and experimental autoimmune encephalomyelitis
    Smriti M Agrawal
    Hotchkiss Brain Institute and Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada
    J Neurosci 31:669-77. 2011
    ..Together, our results are the first to emphasize a role for EMMPRIN in MS and EAE, whereby EMMPRIN regulates leukocyte trafficking through increasing MMP activity. These results identify EMMPRIN as a novel therapeutic target in MS...
  48. ncbi White matter plasticity and enhanced remyelination in the maternal CNS
    Christopher Gregg
    Hotchkiss Brain Institute, Department of Cell Biology, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada T2N 4N1
    J Neurosci 27:1812-23. 2007
    ..This suggests that maternal white matter plasticity imparts a striking ability to repair demyelination and identifies prolactin as a potential therapeutic agent...
  49. ncbi Continued disease activity in a patient with multiple sclerosis after allogeneic hematopoietic cell transplantation
    Jian Qiang Lu
    Department of Pathology, Foothills Medical Centre, University of Calgary, 1403 29th St NW, Calgary, Alberta T2N 2T9, Canada
    Arch Neurol 66:116-20. 2009
    ..To examine the effect of allogeneic hematopoietic cell transplantation (HCT) on disease activity in a patient with multiple sclerosis (MS)...
  50. ncbi Targeting MMPs in acute and chronic neurological conditions
    V Wee Yong
    Hotchkiss Brain Institute, Department of Clinical Neurosciences and Oncology, University of Calgary, Calgary, Alberta, T2N 4N1, Canada
    Neurotherapeutics 4:580-9. 2007
    ..In this review we have used spinal cord injury and multiple sclerosis as examples of acute and chronic neurological conditions, respectively, and we consider the use of MMP inhibitors in these states...
  51. ncbi The many faces of EMMPRIN - roles in neuroinflammation
    Smriti M Agrawal
    Hotchkiss Brain Institute, Department of Clnical Neurosciences and Oncology, University of Calgary, Alberta, Canada
    Biochim Biophys Acta 1812:213-9. 2011
    ....
  52. ncbi Vulnerability of human neurons to T cell-mediated cytotoxicity
    Fabrizio Giuliani
    Department of Oncology, University of Calgary, Calgary, Alberta, Canada
    J Immunol 171:368-79. 2003
    ....
  53. ncbi Myelin formation during development of the CNS is delayed in matrix metalloproteinase-9 and -12 null mice
    Peter H Larsen
    Hotchkiss Brain Institute, Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, T2N 4N1, Canada
    J Neurosci 26:2207-14. 2006
    ..Finally, we found IGFBP-6 levels to remain high in MMP-deficient mice. These results reveal a novel function for MMP-9 and -12 in developmental myelination likely through regulating IGF-1 bioavailability...
  54. ncbi Pilot study of minocycline in relapsing-remitting multiple sclerosis
    Yunyan Zhang
    Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada
    Can J Neurol Sci 35:185-91. 2008
    ..The goal in this study was to evaluate minocycline for its safety, tolerability, and MRI impact as a potential therapy over 36 months after a three month run-in in ten relapsing-remitting (RR) MS patients...
  55. ncbi Reduction of PrP(C) in human cerebrospinal fluid after spinal cord injury
    Anna Carnini
    Hotchkiss Brain Institute, Department of Physiology and Pharmacology, University of Calgary, Calgary, AL, CA
    Prion 4:80-6. 2010
    ..Given that normal PrP(C) has been proposed to be neuroprotective we speculate that the decrease in CSF PrP(C) levels may influence neuronal cell survival following spinal cord injury...
  56. ncbi Combination of thrombin and matrix metalloproteinase-9 exacerbates neurotoxicity in cell culture and intracerebral hemorrhage in mice
    Mengzhou Xue
    Hotchkiss Brain Institute and Department of Clinical Neuroscience, University of Calgary, Calgary, Alberta, Canada T2N 4N1
    J Neurosci 26:10281-91. 2006
    ..To improve the prognosis of ICH, the neurotoxic actions of thrombin and MMP-9 must be inhibited early and simultaneously after injury...
  57. ncbi Interleukin-1beta promotes oligodendrocyte death through glutamate excitotoxicity
    Jennifer L Takahashi
    Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada
    Ann Neurol 53:588-95. 2003
    ....
  58. ncbi Predominance of Th2 polarization by vitamin D through a STAT6-dependent mechanism
    Scott Sloka
    Hotchkiss Brain Institute and the Department of Clinical Neurosciences University of Calgary, Calgary, Alberta, Canada
    J Neuroinflammation 8:56. 2011
    ..Less clear has been the impact of vitamin D on the pro-inflammatory Th17 subset, and whether and how vitamin D may preferentially drive the polarization of one of the T helper subsets...
  59. ncbi Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis
    Veronika Brundula
    Department of Clinical Neurosciences, University of Calgary, Canada
    Brain 125:1297-308. 2002
    ..These results indicate that minocycline may constitute a safe and inexpensive therapy for multiple sclerosis...
  60. ncbi Matrix metalloproteinase-9 facilitates remyelination in part by processing the inhibitory NG2 proteoglycan
    Peter H Larsen
    Neuroscience Research Group and the Department of Oncology, University of Calgary, Calgary, Alberta, Canada T2N 4N1
    J Neurosci 23:11127-35. 2003
    ..These results emphasize for the first time that upregulation of MMP activity can be important for facilitating regeneration from some types of CNS injury...
  61. ncbi A novel MRI texture analysis of demyelination and inflammation in relapsing-remitting experimental allergic encephalomyelitis
    Yunyan Zhang
    Department of Radiology, University of Calgary, Calgary, Alberta, Canada
    Med Image Comput Comput Assist Interv 9:760-7. 2006
    ..This suggests that this new local spatial-frequency measure of image texture may provide a sensitive and precise indication of disease activity...
  62. ncbi 3T deep gray matter T2 hypointensity correlates with disability over time in stable relapsing-remitting multiple sclerosis: a 3-year pilot study
    Y Zhang
    Department of Clinical Neurosciences, University of Calgary, Canada
    J Neurol Sci 297:76-81. 2010
    ..Further studies are required to confirm these results in a large sample and to determine if T2 hypointensity changes in clinically active MS patients...
  63. ncbi Glatiramer acetate in combination with minocycline in patients with relapsing--remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial
    L M Metz
    Department of Clinical Neuroscience, University of Calgary, Calgary, Alberta, Canada
    Mult Scler 15:1183-94. 2009
    ..We conclude that efficacy endpoints showed a consistent trend favoring combination treatment. As minocycline is a relatively safe oral therapy, further study of this combination is warranted in relapsing-remitting multiple sclerosis...
  64. ncbi Susceptibility-weighted imaging in the experimental autoimmune encephalomyelitis model of multiple sclerosis indicates elevated deoxyhemoglobin, iron deposition and demyelination
    Nabeela Nathoo
    University of Calgary, Canada
    Mult Scler 19:721-31. 2013
    ..The contribution of deoxyhemoglobin to the signals seen in SWI has not been well characterized in MS...
  65. ncbi Overcoming neurite-inhibitory chondroitin sulfate proteoglycans in the astrocyte matrix
    Rowena C Cua
    Hotchkiss Brain Institute and the Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada
    Glia 61:972-84. 2013
    ..These findings highlight ADAMTS-4 as a superior protease for overcoming CSPG inhibition of axonal regeneration in the CNS...
  66. ncbi Immunopathogenesis of multiple sclerosis
    Smriti M Agrawal
    Department of Clinical Neuroscience, University of Calgary Calgary, Alberta T2N 4N1, Canada
    Int Rev Neurobiol 79:99-126. 2007
    ..With this background, we discuss the mechanisms of the immunomodulators that are used to treat MS...
  67. ncbi Chondroitin sulphate proteoglycans: extracellular matrix proteins that regulate immunity of the central nervous system
    Sarah Haylock-Jacobs
    Hotchkiss Brain Institute and the Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta Canada
    Autoimmun Rev 10:766-72. 2011
    ..Lastly, we address how CSPGs may be manipulated to improve disease outcomes...
  68. ncbi Minocycline for axonal regeneration after nerve injury: a double-edged sword
    Steve Casha
    Department of Clinical Neurosciences and Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada
    Exp Neurol 213:245-8. 2008
  69. ncbi Exploitation of astrocytes by glioma cells to facilitate invasiveness: a mechanism involving matrix metalloproteinase-2 and the urokinase-type plasminogen activator-plasmin cascade
    Duc M Le
    Department of Oncology, University of Calgary, Calgary, Alberta, Canada
    J Neurosci 23:4034-43. 2003
    ..We conclude that glioma cells exploit their astrocyte environment to activate MMP-2 and that this leads to the increased invasiveness of glioma cells...
  70. ncbi The clinical response to minocycline in multiple sclerosis is accompanied by beneficial immune changes: a pilot study
    R K Zabad
    Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada
    Mult Scler 13:517-26. 2007
    ..The activity of matrix metalloproteinase-9 was decreased by treatment. Thus, clinical and MRI outcomes are supported by systemic immunological changes and call for further investigation of minocycline in MS...
  71. ncbi CXCR4 is a major chemokine receptor on glioma cells and mediates their survival
    Yan Zhou
    Departments of Oncology and Clinical Neurosciences, University of Calgary, 3330 Hospital Drive NW, Calgary, Alberta T2N 4N1, Canada
    J Biol Chem 277:49481-7. 2002
    ..We conclude that glioma cells express a predominant chemokine receptor, CXCR4, and that this functions to regulate survival in part through activating pathways such as Akt...
  72. ncbi Differential mechanisms of action of interferon-beta and glatiramer aetate in MS
    V Wee Yong
    Department of Oncology and Clinical Neurosciences, University of Calgary, Alberta, Canada
    Neurology 59:802-8. 2002
    ..Other differences are also emphasized. The presence of GA-reactive lymphocytes within the CNS parenchyma may have the additional benefit of conferring neuroprotection through protective autoimmunity...
  73. ncbi Cytokine production in T lymphocyte-microglia interaction is attenuated by glatiramer acetate: a mechanism for therapeutic efficacy in multiple sclerosis
    S Chabot
    Department of Clinical Neurosciences, Faculty of Medicine, University of Calgary, Alberta, Canada
    Mult Scler 8:299-306. 2002
    ..The net result of a non-inflammatory milieu within the CNS, in spite of T cell infiltration, may help account for the amelioration of disease activity in MS patients on glatiramer acetate therapy...
  74. ncbi Immune-mediated neurodegeneration and neuroprotection in MS
    F Giuliani
    University of Calgary, Department of Clinical Neurosciences, 3330 Hospital Drive, Calgary, Alberta, T2N 4N1, Canada
    Int MS J 10:122-30. 2003
    ..In this review we analyse the findings of immune-mediated injury in MS and focus on axonal and neuronal injury. The potential neuroprotective role of some currently available MS drug treatments is also discussed...
  75. ncbi Astrocytes attenuate oligodendrocyte death in vitro through an alpha(6) integrin-laminin-dependent mechanism
    S M Corley
    Department of Oncology, University of Calgary, Calgary, Alberta, Canada
    Glia 36:281-94. 2001
    ..Enhancing this interaction may provide for OL survival in neurological injury...
  76. ncbi HIV-1 Tat neurotoxicity is prevented by matrix metalloproteinase inhibitors
    J B Johnston
    Department of Clinical Neuroscience, University of Calgary, Canada
    Ann Neurol 49:230-41. 2001
    ..005). These findings indicate that Tat causes neuronal death through an indirect mechanism that is Tat sequence dependent and involves the induction of MMPs...
  77. ncbi Analyses of all matrix metalloproteinase members in leukocytes emphasize monocytes as major inflammatory mediators in multiple sclerosis
    Amit Bar-Or
    Montreal Neurological Institute, Quebec, Canada
    Brain 126:2738-49. 2003
    ....
  78. ncbi Metalloproteinases are enriched in microglia compared with leukocytes and they regulate cytokine levels in activated microglia
    Robert K Nuttall
    School of Biological Sciences, University of East Anglia, Norwich, United Kingdom
    Glia 55:516-26. 2007
    ..The results have implications for the regulation of neuroinflammation and its outcomes following CNS injuries...
  79. ncbi Neurodegeneration and neuroprotection in multiple sclerosis and other neurodegenerative diseases
    Suhayl Dhib-Jalbut
    UMDNJ Robert Wood Johnson Medical School, New Brunswick, NJ 08901, and The Cleveland Clinic, OH, USA
    J Neuroimmunol 176:198-215. 2006
    ..Elucidating the mechanisms that orchestrate neuronal diseases should facilitate development of neuroprotective and neurorestorative strategies...
  80. ncbi Minocycline reduces gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis
    Luanne M Metz
    Ann Neurol 55:756. 2004